Welcome to our dedicated page for Purple Biotech news (Ticker: PPBT), a resource for investors and traders seeking the latest updates and insights on Purple Biotech stock.
Purple Biotech Ltd. develops oncology immunotherapies as a clinical-stage biotechnology company with American depositary shares traded under PPBT. Its recurring updates center on CAPTN-3, a platform of capped or masked tri-specific antibodies designed to target tumor-associated antigens while engaging both T cells and NK cells in the tumor microenvironment.
Company news commonly covers preclinical data, toxicology and manufacturing work for IM1240, the 5T4-targeting lead CAPTN-3 antibody, and IM1305, the TROP2-targeting development candidate. Other recurring themes include oncology research collaborations, scientific advisory activity, financial results, ADR and capital-structure actions, Nasdaq listing compliance, and governance updates.
Purple Biotech (PPBT) received a U.S. Patent and Trademark Office Notice of Allowance for a patent application covering tri-specific antibody constructs and methods of use, further protecting its CAPTN-3 modular platform for conditionally activated multispecific antibodies.
The allowed U.S. patent covers constructs with dual tumor-associated antigen (TAA) binders and other CAPTN-3 features, reinforcing protection for the platform’s modular architecture and its ability to generate new tri-specific antibodies by exchanging targeting and functional domains. Purple Biotech states that this flexibility is intended to accelerate development of new oncology candidates and enhance future development and partnering potential. The CAPTN-3 platform’s lead candidate, IM1240, is advancing toward the clinic, with a second candidate, IM1305, in preclinical development alongside other clinical-stage assets CM24 and NT219.
Purple Biotech (NASDAQ/TASE: PPBT) reported financial results for the three and six months ended June 30, 2026, and highlighted new preclinical data for its CAPTN-3 tri-specific T-cell engager platform, led by IM1240, which is aimed to enter first-in-human clinical studies in 2027.
According to Purple Biotech, IM1240 showed an approximately 8-fold longer half-life and 16-fold greater systemic exposure than a non-capped variant in non-human primates, with mitigated cytokine release and a broad therapeutic window. Patient-derived tumor models from resistant HNSCC, bladder cancer and NSCLC samples all responded to IM1240, with NKG2A engagement deemed essential for full activity.
For Q2 2026, research and development expenses were $0.7 million and general and administrative expenses were $0.6 million, resulting in an operating loss of $1.3 million. Cash, cash equivalents and short-term deposits totaled $6.1 million as of June 30, 2026, which management estimates will fund operations through mid‑2027.
Purple Biotech (NASDAQ/TASE: PPBT) presented new preclinical data on its CAPTN-3 T‑cell engager IM1240 at EACR 2026. In non-human primates, IM1240 showed an ~8-fold longer half-life, 16-fold higher exposure, and reduced cytokine release versus non-capped variants, supporting a broad therapeutic window.
In PD‑1- and chemotherapy-resistant patient-derived head and neck, bladder, and NSCLC samples, IM1240 induced cancer cell apoptosis, immune remodeling, and formation of tertiary lymphoid structures, with the NKG2A arm identified as essential for full anti-tumor activity. These data support advancing IM1240 toward a planned first-in-human study in 2027.
Purple Biotech (NASDAQ/TASE: PPBT) reported Q1 2026 results and pipeline progress. New IM1240 tri-specific antibody data showed anti-tumor activity across all tested, treatment-resistant patient-derived samples. The company formed a CAPTN-3 Scientific Advisory Board and expanded its Converge Bio AI collaboration.
R&D expenses were $1.2M and G&A $1.0M. Adjusted operating loss and adjusted net loss were each $2.1M. Finance income, net was $2.2M, leading to a reported net loss of $0.1M. Cash and deposits totaled $6.4M, with runway expected into 2027.
Purple Biotech (NASDAQ: PPBT) reported preclinical IM1240 data showing anti-tumor activity across seven patient-derived tumor samples.
IM1240 is a conditionally activated capped-CD3 × 5T4 × NKG2A tri-specific antibody; the NKG2A arm enhanced activity, and NSCLC explants showed induction of mature tertiary lymphoid structures with increased CD8 and NK cells.
Purple Biotech (NASDAQ: PPBT) announced the formation of a Scientific Advisory Board to support advancement of its CAPTN-3 tri‑specific antibody platform toward clinical-stage immunotherapy development. The SAB includes experts with direct experience in NK and T‑cell engagers and in the clinical development of approved T‑cell therapies.
The board will advise on translational science, NK and T cell biology, and clinical strategy as Purple advances CAPTN-3 toward first-in-human studies.
Purple Biotech (NASDAQ: PPBT) announced a collaboration with Converge Bio on March 25, 2026 to apply proprietary generative AI to accelerate and optimize its next-generation tri-specific antibody platform for oncology. The partnership targets faster discovery, improved developability, and expanded capability against solid-tumor targets.
The collaboration will integrate Converge Bio's AI-driven molecule design with Purple Biotech's CAPTN-3 conditional activation technology to generate optimized T cell engagers and additional high-quality candidates.
Purple Biotech (NASDAQ: PPBT) announced it regained compliance with Nasdaq Listing Rule 5550(a)(2) after its American Depositary Shares maintained a minimum closing bid of $1.00 or more for at least 10 consecutive business days, a condition met on March 13, 2026. The company is now compliant with Nasdaq listing standards.
The company is a clinical-stage immunotherapy developer advancing lead candidates IM1240 and IM1305 and maintaining other clinical-stage assets pending partnering or investment.
Purple Biotech (NASDAQ/TASE: PPBT) announced that Gil Efron will step down as CEO effective August 2026 for health reasons and will transition to lead corporate development while remaining on the Board.
The Board has begun a formal CEO search; the company highlighted continued focus on the CAPTN-3 tri-specific antibody platform and an orderly leadership transition.
Purple Biotech (NASDAQ:PPBT) reported Q4 and full-year 2025 results highlighting advancement of its CAPTN-3 tri-specific antibody program. Lead molecules IM1240 and IM1305 showed positive preclinical efficacy, expanded toxicology window and commercially viable manufacturing yield.
Key figures: cash $9.5M (Dec 31, 2025) with runway into 2027, $20.5M impairment for CM24/NT219, and $26.4M net loss for 2025.